BRIEF-Genmab and GSK gets EU approval for Arzerra in combination

COPENHAGEN, July 3 Thu Jul 3, 2014 9:26am EDT

Related Topics

COPENHAGEN, July 3 (Reuters) - Danish biotech company Genmab :

* GlaxoSmithKline (GSK) and Genmab receive EU authorization for Arzerra (Ofatumumab) as first-line treatment for chronic lymphocytic leukemia (Cll) in combination with chlorambucil or bendamustine for patients ineligible for flud

* Approval based on phase III data from study with ofatumumab + chlorambucil & phase II data from study with ofatumumab and bendamustine

Source text for Eikon: Further company coverage: (Reporting by Copenhagen newsroom)

FILED UNDER:
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.